Monopar Therapeutics MNPR
We take great care to ensure that the data presented and summarized in this overview for Monopar Therapeutics is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MNPR
Top Purchases
Top Sells
About MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Insider Transactions at MNPR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 14
2025
|
Kim R Tsuchimoto Director |
SELL
Open market or private sale
|
Direct |
8,904
-43.67%
|
$356,160
$40.0 P/Share
|
|
Jul 14
2025
|
Kim R Tsuchimoto Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
8,904
+30.4%
|
-
|
|
Jul 14
2025
|
Chandler Robinson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,800
-18.61%
|
$672,000
$40.0 P/Share
|
|
Jul 14
2025
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
16,800
+15.69%
|
-
|
|
Jul 14
2025
|
Christopher M Starr Director |
SELL
Open market or private sale
|
Direct |
16,800
-76.46%
|
$672,000
$40.0 P/Share
|
|
Jul 14
2025
|
Christopher M Starr Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
16,800
+43.33%
|
-
|
|
Jun 30
2025
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,865
-7.39%
|
$205,275
$35.78 P/Share
|
|
Jun 30
2025
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,344
+14.4%
|
-
|
|
Jun 30
2025
|
Andrew Cittadine Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,990
-6.12%
|
$104,650
$35.78 P/Share
|
|
Jun 30
2025
|
Andrew Cittadine Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,863
+12.32%
|
-
|
|
Apr 02
2025
|
Tactic Pharma LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
33,334
-3.9%
|
$1,166,690
$35.0 P/Share
|
|
Mar 31
2025
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,204
-1.79%
|
$43,344
$36.41 P/Share
|
|
Mar 31
2025
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,106
+5.76%
|
-
|
|
Mar 31
2025
|
Andrew Cittadine Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
744
-1.74%
|
$26,784
$36.41 P/Share
|
|
Mar 31
2025
|
Andrew Cittadine Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,791
+4.02%
|
-
|
|
Mar 04
2025
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,759
-2.71%
|
$54,529
$31.7 P/Share
|
|
Mar 04
2025
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,002
+8.47%
|
-
|
|
Dec 31
2024
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,209
-3.62%
|
$48,598
$22.0 P/Share
|
|
Dec 31
2024
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,895
+7.42%
|
-
|
|
Dec 31
2024
|
Andrew Cittadine Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
721
-1.73%
|
$15,862
$22.0 P/Share
|
Last 12 Months Summary
| Exercise of in-the-money or at-the-money derivatives securities | 42.5K shares |
|---|---|
| Exercise of conversion of derivative security | 45.5K shares |
| Open market or private purchase | 1.55K shares |
| Open market or private sale | 75.8K shares |
|---|---|
| Payment of exercise price or tax liability | 17.9K shares |
| Other acquisition or disposition | 1.43M shares |